WO2004083388A3 - Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 - Google Patents

Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 Download PDF

Info

Publication number
WO2004083388A3
WO2004083388A3 PCT/US2004/007618 US2004007618W WO2004083388A3 WO 2004083388 A3 WO2004083388 A3 WO 2004083388A3 US 2004007618 W US2004007618 W US 2004007618W WO 2004083388 A3 WO2004083388 A3 WO 2004083388A3
Authority
WO
WIPO (PCT)
Prior art keywords
hgprbmy74
polypeptides
polynucleotide encoding
coupled receptor
protein coupled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/007618
Other languages
French (fr)
Other versions
WO2004083388A2 (en
Inventor
Chandra S Ramanathan
John N Feder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to EP04720415A priority Critical patent/EP1603585A2/en
Publication of WO2004083388A2 publication Critical patent/WO2004083388A2/en
Publication of WO2004083388A3 publication Critical patent/WO2004083388A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides novel polynucleotides encoding HGPRBMY74 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY74 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
PCT/US2004/007618 2003-03-14 2004-03-12 Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 Ceased WO2004083388A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04720415A EP1603585A2 (en) 2003-03-14 2004-03-12 Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45494203P 2003-03-14 2003-03-14
US60/454,942 2003-03-14

Publications (2)

Publication Number Publication Date
WO2004083388A2 WO2004083388A2 (en) 2004-09-30
WO2004083388A3 true WO2004083388A3 (en) 2005-04-21

Family

ID=33029930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007618 Ceased WO2004083388A2 (en) 2003-03-14 2004-03-12 Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74

Country Status (3)

Country Link
US (2) US7094572B2 (en)
EP (1) EP1603585A2 (en)
WO (1) WO2004083388A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US20080089881A1 (en) * 2005-12-07 2008-04-17 Jun Li Treatment and Diagnostics of Inflammatory Diseases
KR20080091814A (en) 2006-01-20 2008-10-14 쉐링 코포레이션 Heterocycle as a Nicotinic Acid Receptor Agonist for the Treatment of Lipidemia Disorders
EP2599641B1 (en) * 2006-08-07 2015-06-10 NSK Ltd. Bearing unit raceway ring member, bearing unit, and method and apparatus for manufacturing bearing unit raceway ring member
KR20100065190A (en) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 Drug carriers
JP6031718B2 (en) * 2011-09-20 2016-11-30 国立大学法人 熊本大学 Alpha2-macroglobulin neuroprotective effect inhibitor using lipoprotein and ophthalmic composition
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12496310B2 (en) 2017-06-30 2025-12-16 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy
CA3068634A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
CA3068636A1 (en) * 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
CA3122758A1 (en) * 2018-12-20 2020-06-25 Agriculture Victoria Services Pty Ltd Method of protein extraction from cannabis plant material

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013845A2 (en) * 2000-08-18 2002-02-21 Novartis Ag Inflammation related g-protein coupled receptor

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897992A (en) 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US20030068382A1 (en) 1999-05-18 2003-04-10 Samuel Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US7807136B2 (en) 1997-01-13 2010-10-05 David S. Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
JP2002508660A (en) 1997-06-12 2002-03-19 スミスクライン ビーチャム コーポレーション HM74A receptor
US20040137563A9 (en) 1998-10-13 2004-07-15 Ruoping Chen Endogenous and non-endogenous versions of human G protein-coupled receptors
CA2371093A1 (en) 1999-04-26 2000-11-02 David M. Manyak Receptor selectivity mapping
US20040117125A1 (en) 1999-04-26 2004-06-17 Hao Chen Drug discovery method and apparatus
US20020187514A1 (en) 1999-04-26 2002-12-12 Hao Chen Identification of molecular targets useful in treating substance abuse and addiction
US6955873B1 (en) 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
IL149569A0 (en) 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
AU6604901A (en) 2000-06-05 2001-12-17 Bayer Aktiengesellschaft Regulation of human hm74-like g protein coupled receptor
FR2814952B1 (en) 2000-10-06 2004-01-02 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICROMIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
US6833447B1 (en) 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US20030078218A1 (en) 2001-08-15 2003-04-24 Gabor Jarai Inflammation related G-protein coupled receptor
GB0021484D0 (en) 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
MXPA03007984A (en) 2001-03-07 2003-12-04 Bristol Myers Squibb Co Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27.
US20040254224A1 (en) 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
US20030143668A1 (en) 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20040038201A1 (en) 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
JP2005514934A (en) 2002-01-23 2005-05-26 アベンティス・ファーマスーティカルズ・インコーポレイテツド Nucleic acids encoding G protein-coupled receptors and uses thereof
EP1477806A4 (en) 2002-02-22 2006-09-06 Takeda Pharmaceutical METHOD OF DETERMINING A LIGAND
JP2004049004A (en) 2002-05-31 2004-02-19 Japan Science & Technology Corp 5-oxo-ETE receptor protein and its gene
JP2004065120A (en) 2002-08-07 2004-03-04 Sumitomo Pharmaceut Co Ltd Disease marker for inflammatory bowel disease and use thereof
MXPA05001702A (en) 2002-08-14 2005-04-19 Neurosearch As Novel quinuclidine derivatives and their use.
AU2003300776A1 (en) 2002-09-09 2004-05-25 Omeros Corporation G protein coupled receptors and uses thereof
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003300014A1 (en) 2002-10-10 2004-05-04 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
JP4103537B2 (en) 2002-10-17 2008-06-18 アステラス製薬株式会社 New screening method
US7038085B2 (en) 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2503786A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNE SYSTEM
DE10251244A1 (en) 2002-11-04 2004-05-19 Universität Heidelberg Method for detecting compounds with antihyperlipemic activity, useful for identifying therapeutic agents, is based on their interaction with nicotinic acid receptors
AU2003291342A1 (en) 2002-11-05 2004-06-07 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
EP1562945B1 (en) 2002-11-11 2006-11-15 Neurosearch A/S 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
WO2004053454A2 (en) 2002-11-27 2004-06-24 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods for detecting invasion of a cell
ES2462545T3 (en) 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research A procedure for the determination of a selective cholinergic agonist for a nicotinic alpha7 receptor
JP2006510664A (en) 2002-12-06 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Crystalline fumarate salt of 1-azabicyclo [2.2.2] octo-substituted furo [2,3-c] pyridinylcarboxamide, composition containing the salt, and process for producing the same
AU2003283648A1 (en) 2002-12-06 2004-06-30 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP2004198202A (en) 2002-12-17 2004-07-15 Takeda Chem Ind Ltd Novel screening method
JP2007524566A (en) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ Methods for modulating the interaction between receptors and ligands
BRPI0406834A (en) 2003-01-22 2005-12-27 Pharmacia & Upjohn Co Llc Treatment of disease with nach alfa-7 total receptor agonists
US20050059153A1 (en) 2003-01-22 2005-03-17 George Frank R. Electromagnetic activation of gene expression and cell growth
US20050084872A1 (en) 2003-01-24 2005-04-21 Lum Pek Y. Methods for determining whether an agent possesses a defined biological activity
EP1597586A2 (en) 2003-02-13 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with hm74
WO2004071378A2 (en) 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004072648A1 (en) 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox2r (ox2r)
EP1599476B1 (en) 2003-02-27 2009-10-14 Neurosearch A/S Novel diazabicyclic aryl derivatives
BRPI0407616A (en) 2003-03-07 2006-02-14 Lilly Co Eli compound, pharmaceutical composition, method to block a combination of mu receptor, hood, delta (heterodimer) thereof in mammals, method to treat or prevent obesity and related diseases, use of a compound, and method of suppressing appetite in a patient in need of this "
EP1651772A1 (en) 2003-03-07 2006-05-03 Arcturus Bioscience, Inc. Breast cancer signatures
US20040180332A1 (en) 2003-03-12 2004-09-16 Millennium Pharmaceuticals, Inc. Methods and compositions for treating aids and HIV-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777
WO2004083818A2 (en) 2003-03-17 2004-09-30 Rinat Neuroscience Corp. Methods of identifying drug targets and modulators of neurons and compositions comprising the same
WO2004085433A2 (en) 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2520870A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1613615A2 (en) 2003-04-03 2006-01-11 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
AU2004227833B2 (en) 2003-04-04 2009-10-01 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
AU2004227854B2 (en) 2003-04-04 2009-07-23 Merck & Co., Inc. Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US20060234242A1 (en) 2003-04-07 2006-10-19 Ribonomics, Inc. Methods for identifying therapeutic targets involved in glucose and lipid metabolism
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
WO2004099202A1 (en) 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US20040224962A1 (en) 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
AR041089A1 (en) 2003-05-15 2005-05-04 Merck & Co Inc PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20040242644A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (IS-5S)-3-(5,6-dichloro-3-pyridinyl-)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
WO2004108899A2 (en) 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004111197A2 (en) 2003-06-10 2004-12-23 Trustees Of Boston University Gene expression signatures, methods and compositions for diagnosing disorders of the lung
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
CA2528834A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
MXPA06000892A (en) 2003-07-21 2006-03-30 Pfizer Prod Inc Aryl fused azapolycyclic compounds.
ES2331245T3 (en) 2003-07-21 2009-12-28 Pfizer Products Inc. AZAPOLICICLIC COMPOUNDS CONDENSED WITH HETEROARILO THAT REDUCE THE ADDICTION TO NICOTINE.
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
DE602004008658T2 (en) 2003-09-05 2008-06-12 Cellzome Ag TREATMENT OF NEURODEGENERATIVE DISEASES
WO2005023858A1 (en) 2003-09-05 2005-03-17 Cellzome Ag Protein complexes associated with app-processing
EP1678172B1 (en) 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclic compounds for relieving pain and treating central nervous system disorders
WO2005041971A1 (en) 2003-10-21 2005-05-12 Merck & Co., Inc. Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain
WO2005041878A2 (en) 2003-10-29 2005-05-12 Tawakol Raif M D Compositions and methods for increasing hdl and hdl-2b levels
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US20050209181A1 (en) 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US7151097B2 (en) 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7816356B2 (en) 2003-11-14 2010-10-19 Daniel Yohannes Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
EP1687275A4 (en) 2003-11-21 2009-01-14 Merck & Co Inc PYRIDIN-4-YLAMINE COMPOUNDS SUITABLE FOR THE TREATMENT OF NEUROPATHIC PAIN
US20070093545A1 (en) 2003-11-21 2007-04-26 Arena Pharmaceuticals, Inc. 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
JP2005198640A (en) 2003-11-25 2005-07-28 Biomarker Science:Kk Method for expressing gene
SI1541197T1 (en) 2003-12-02 2009-08-31 Pharmaneuroboost N V Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
DE602004010299T2 (en) 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. INDOLE, 1H-INDAZOLE, 1,2-BENZISOXAZOLE AND 1,2-BENZISOTHIAZOLE AND THEIR PREPARATION AND APPLICATIONS
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
WO2005066129A2 (en) 2003-12-31 2005-07-21 University Of Kentucky Research Foundation Bis-pyridino containing compounds for use in the treatment of cns pathologies
WO2005067649A2 (en) 2004-01-08 2005-07-28 The Ohio State University Use of databases to create gene expression microarrays
EP1713809B1 (en) 2004-02-04 2009-07-29 Neurosearch A/S Dimeric azacyclic compounds and their use
CA2555311A1 (en) 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
WO2005076939A2 (en) 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease
HRP20130406T1 (en) 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medicaments with hm74a receptor activity
KR20060127141A (en) 2004-02-20 2006-12-11 아벤티스 파마슈티칼스 인크. Furosemide derivatives as modulators of HM74 and its use for the treatment of inflammation
ME00059B (en) 2004-02-20 2010-06-10 Oxydecahydronaphthalene modulators of hm74
CA2558366A1 (en) 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
JP2005253442A (en) 2004-03-09 2005-09-22 Hitachi Medical Corp Gene group having expression profile different between human dental pulp stem cell and mesenchymal stem cell
DE102004016437A1 (en) 2004-04-04 2005-10-20 Oligene Gmbh Method for detecting signatures in complex gene expression profiles
WO2005103052A1 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
US20060003959A1 (en) * 2004-06-10 2006-01-05 Steven Burden Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
WO2006023312A2 (en) * 2004-08-20 2006-03-02 Carl Deirmengian Diagnostic assay for source of inflammation
US20060154275A1 (en) * 2004-12-02 2006-07-13 The Board Of Trustees Of The Leland Stanford Junior University Regulated genes in cervical cancer
EP1677113A1 (en) 2004-12-29 2006-07-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Method for the identification of protein-protein interactions in disease related protein networks
KR100955112B1 (en) * 2005-06-14 2010-04-28 에프. 호프만-라 로슈 아게 Anthranilic acid derivatives
DK1901731T3 (en) * 2005-06-28 2011-06-14 Merck Sharp & Dohme Niacin receptor agonists, compositions containing such compounds and methods of treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013845A2 (en) * 2000-08-18 2002-02-21 Novartis Ag Inflammation related g-protein coupled receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOMURA ET AL: "Molecular Cloning of CDNAs Encoding a LD78 Receptor and Putative Leukocyte Chemotactic Peptide Receptors", INTERNATIONAL IMMUNOLOGY, vol. 5, no. 10, 1993, pages 1239 - 1249, XP002911511 *

Also Published As

Publication number Publication date
US7094572B2 (en) 2006-08-22
WO2004083388A2 (en) 2004-09-30
US7371822B2 (en) 2008-05-13
EP1603585A2 (en) 2005-12-14
US20050227238A1 (en) 2005-10-13
US20060177903A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2005026317A3 (en) Polynucleotides encoding novel variants of the trp channel family member, ltrpc3
WO2008105797A3 (en) Polynucleotides encoding novel pcsk9 variants
WO2005001061A3 (en) Polynucleotides encoding novel adiponectin receptor variants
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
WO2002072751A3 (en) Polynucleotides encoding a metalloprotease, mp-1
WO2001055367A8 (en) Nucleic acids, proteins, and antibodies
WO2002083856A3 (en) Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
WO2002094999A3 (en) Polynucleotide encoding a novel trp channel family member, trp-plik2, and splice variants thereof
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2002088303A3 (en) Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2002057460A3 (en) Polynucleotides encoding human phosphatases
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2005052123A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor variant of the relaxin receptor, hgprbmy5v1, and variants thereof
WO2004094621A3 (en) Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
WO2003048316A3 (en) Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
WO2004090097A3 (en) Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2002066606A3 (en) Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
WO2002072755A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27
WO2003012063A3 (en) Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
WO2003079746A3 (en) A novel human g-protein coupled receptor, hgprbmy14, related to the orphan gpcr, gpr73
WO2002077173A3 (en) Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof
WO2003083076A3 (en) Polynucleotides encoding novel two splice variants of a human cell surface protein with immunologobulin folds, bgs5g and bgs5i

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004720415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004720415

Country of ref document: EP